Depsipeptides

12/01/2007 - "Moreover, depsipeptide treatment before adenoviral vector injection significantly improved transgene expression at tumor sites. "
12/01/2007 - "Sensitization of tumor cells with depsipeptide can improve the efficacy of adenoviral vector-mediated suicide gene therapy. "
01/09/2023 - "Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials."
03/01/2015 - "In particular, the potent effects of cyclic depsipeptides on tumor cells have led to a number of clinical trials evaluating their potential as chemotherapeutic agents. "
08/01/2006 - "Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report."

02/20/2007 - "Depsipeptide showed therapeutic efficacy in Phase I trial of patients with malignant lymphoma. "
03/01/2008 - "This study suggests that depsipeptide may have potential usefulness for gene delivery in patients with lymphoma."
07/01/2005 - "In many cases, the empirical observations from early clinical trials have provided invaluable clues to potentially valuable drugs like bortezomib, depsipeptide, and SAHA, These empirical observations, based on the inclusion of patients with lymphoma on these studies, have thus far proven to be as or more valuable than any other 'rational' target based approach. "
03/01/2008 - "The results demonstrate that PEI/DNA complexes post-incubated with depsipeptide can enhance the transfection efficiency in the Raji human lymphoma cell line. "
02/05/2009 - "Depsipeptide, a histone deacetylase inhibitor, has demonstrated major antitumor effects in leukemias and lymphomas. "

01/01/2004 - "While there were sporadic case reports of activity using the early generation HDIs, dramatic responses have recently been observed in patients with T-cell lymphomas treated with depsipeptide, one of the newer agents. "
06/15/2006 - "Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma."
06/15/2004 - "To better understand the effects of histone deacetylase inhibitors on T-cell lymphoma, the human T-cell lymphoma cell line HUT78 was tested for sensitivity and molecular response to depsipeptide. "
05/01/2004 - "FR901228, FK228, or depsipeptide, is an HDAC inhibitor effective in T-cell lymphomas. "
06/15/2004 - "These studies confirm the activity of depsipeptide in a T-cell lymphoma model and suggest a general sensitivity of T-cell lymphoma to histone deacetylase inhibitors, an emerging new class of anticancer agents."

07/15/2003 - "Depsipeptide is in clinical trials for chronic lymphocytic leukemia (CLL) on the basis of earlier observations demonstrating selective in vitro activity in CLL. "
08/15/1999 - "Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells."
04/01/2005 - "AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway."
02/01/2005 - "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia."
01/01/2004 - "These results were validated in primary leukemia cells from patients with refractory or relapsed AML or chronic lymphocytic leukemia (CLL) treated on a Phase I clinical trial of the HDAC inhibitor depsipeptide. "

07/01/2008 - "In the recent years, we focused our attention on the cyclodepsipeptide Jaspamide 1, an interesting marine metabolite, possessing a potent inhibitory activity against breast and prostate cancer, as a consequence of its ability to disrupt actin cytoskeleton dynamics. "
03/01/2008 - "Depsipeptide (FK228) inhibits growth of human prostate cancer cells."
09/01/2002 - "Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human prostate cancer cell lines. "
09/09/2011 - "Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide."
03/01/2007 - "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells."